CareDx Q4 Revenues Up 64 Percent
The company reported $58.6 million in total revenues for the quarter and said testing services revenues rose 73 percent year over year.
Heart Transplant Cell-Free DNA Test Enables Earlier Detection of Acute Rejection Than Biopsy
The researchers hope that donor-derived cell-free DNA testing to monitor rejection can help relieve racial disparities in heart transplant outcomes.
CareDx Preliminary Q4 Revenues Up 63 Percent, Beat Estimates
CareDx expects fourth quarter revenues of $58.4 million to $58.6 million, an increase of approximately 63 percent compared to $35.8 million in Q4 2019.
CGS Administrators Aligns Medicare Coverage for CareDx AlloSure Tests
The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.
CareDx Q3 Revenues Up 58 Percent
The company reported $53.4 million in total revenues for the quarter and said testing services revenues rose 61 percent year over year.